Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.